President of the United States

05/08/2025 | News release | Distributed by Public on 05/08/2025 08:45

President Trump is Bringing Drug Manufacturing Back

President Trump is Bringing Drug Manufacturing Back

The White House
May 8, 2025

President Donald J. Trump is determined to make the American pharmaceutical and biotechnology industries great again - both as a matter of national security and to unleash unprecedented prosperity for American workers.

Gilead Sciences became the latest industry leader to announce a massive new investment in its U.S. operations with an $11 billion boost to its planned U.S.-based spending.

The company joins a host of others in expanding their domestic footprint to align with President Trump's vision:

  • New Jersey-based Johnson & Johnson announced a $55 billion investment in manufacturing, research and development, and technology.
  • Roche, a Swiss drug and diagnostics company, announced a $50 billion investment in its U.S.-based manufacturing and research and development.
  • New Jersey-based Bristol Myers Squibb announced a $40 billion investment in research, development, technology, and manufacturing.
  • Indiana-based Eli Lilly and Company announced a $27 billion investment to more than double its domestic manufacturing capacity.
  • Novartis, a Swiss drugmaker, announced a $23 billion investment to build or expand ten manufacturing facilities across the U.S.
  • Illinois-based AbbVie announced a $10 billion investment over the next ten years to support volume growth and add four new manufacturing plants to its network.
  • New Jersey-based Merck & Co. announced it will invest a total of $9 billion over the next several years after opening a new $1 billion North Carolina manufacturing facility - including a new state-of-the-art biologics manufacturing plant in Delaware.
    • Merck Animal Health announced an $895 million investment to expand their manufacturing operation in Kansas.
  • New York-based Regeneron Pharmaceuticals announced a $3 billion agreement with FUJIFILM Diosynth Biotechnologies to produce drugs at its North Carolina facility.
  • California-based Amgen announced a $900 million investment in its Ohio-based manufacturing operation.
  • Illinois-based Abbott Laboratories announced a $500 million investment in its Illinois and Texas facilities.
President of the United States published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 14:45 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io